Company Description
Innoviva, Inc. operates as a biopharmaceutical company in the United States and internationally.
Its royalty portfolio includes RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol, and an inhaled corticosteroid, and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist, umeclidinium bromide, and ABA, VI.
The company also markets GIAPREZA for increasing blood pressure in adults with septic or other distributive shock; XACDURO, a co-packaged for intravenous use for the treatment of hospital-acquired and ventilator-associated bacterial pneumonia caused by Acinetobacter; XERAVA for the treatment of complicated intra-abdominal infections in adults; ZEVTERA an advanced-generation cephalosporin antibiotic for the treatment of staphylococcus aureus bacteremia, as well as with right-sided endocarditis, acute bacterial skin and skin structure infections, and community-acquired bacterial pneumonia; NUZOLVENCE for the treatment of uncomplicated urogenital gonorrhea in adults and adolescents.
In addition, the company develops bacteriophages with potential use in a range of infectious and other serious diseases.
It has a strategic partnership with Sarissa Capital Management LP; and LABA Collaboration Agreement with Glaxo Group Limited to develop and commercialize once‑daily products for the treatment of chronic obstructive pulmonary disease and asthma.
The company was formerly known as Theravance, Inc. and changed its name to Innoviva, Inc. in January 2016.
Innoviva, Inc. was incorporated in 1996 and is headquartered in Burlingame, California.
| Country | United States |
| Founded | 1996 |
| IPO Date | Oct 5, 2004 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 159 |
| CEO | Pavel Raifeld |
Contact Details
Address: 1350 Old Bayshore Highway, Suite 400 Burlingame, California 94010 United States | |
| Phone | 650 238 9600 |
| Website | inva.com |
Stock Details
| Ticker Symbol | INVA |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001080014 |
| CUSIP Number | 45781M101 |
| ISIN Number | US45781M1018 |
| Employer ID | 94-3265960 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Pavel Raifeld C.F.A. | Chief Executive Officer and Director |
| Stephen Basso M.B.A. | Chief Financial Officer |
| Marcie Cain | Chief People Officer |
| Patricia M. Drake | Chief Commercial Officer-Innoviva Specialty Therapeutics, Inc. |
| Dr. David Altarac M.D., MPA | Chief Medical Officer of IST |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Feb 25, 2026 | 8-K | Current Report |
| Feb 25, 2026 | 10-K | Annual Report |
| Feb 12, 2026 | SCHEDULE 13G/A | Filing |
| Jan 21, 2026 | SCHEDULE 13G/A | Filing |
| Nov 5, 2025 | 10-Q | Quarterly Report |
| Nov 5, 2025 | 8-K | Current Report |
| Oct 8, 2025 | SCHEDULE 13G/A | Filing |
| Sep 3, 2025 | SCHEDULE 13G/A | Filing |
| Aug 13, 2025 | SCHEDULE 13G/A | Filing |
| Aug 6, 2025 | 10-Q | Quarterly Report |